CCR researchers show selumetinib shrinks tumors in children with NF1

Findings from a phase 2 clinical trial show that the drug selumetinib improves outcomes for children with the genetic disorder neurofibromatosis type 1 (NF1). In the trial, selumetinib shrank the inoperable tumors that develop with NF1 called plexiform neurofibromas, and children experienced reduced pain, improved function, and better overall quality of life after receiving the treatment. This trial was led by Brigitte Widemann, M.D., Chief of the Pediatric Oncology Branch (POB), and Andrea M. Gross, M.D., Assistant Research Physician in POB, and the results were published March 18, 2020, in the New England Journal of Medicine. Read more...

CCR researchers show selumetinib shrinks tumors in children with NF1
Milestones cover

New Milestones publication now available

Mar 12, 2020

Every year, the Center for Cancer Research makes remarkable contributions to the understanding, detection, treatment and prevention of cancer. This issue of our annual publication, Milestonesfeatures some of the most impactful science conducted in the past year in CCR. These advances include new insights into how genomes are organized and how DNA and RNA function in cells, how cellular processes and signaling events function in healthy cells and how they are affected in cancer. Other major discoveries this year include how cancers become metastatic and what drives the proliferation of cancer cells. Read more...

Peter Pinto and Pete Choyke

CCR researchers show testing with combined biopsy method improves prostate cancer diagnosis

Mar 5, 2020

A method of testing for prostate cancer developed at the Center for Cancer Research leads to more accurate diagnosis and prediction of the course of the disease, according to a new study published in the New England Journal of MedicinePeter Pinto, M.D., Investigator in the Urologic Oncology Branch, led the study and says this method, which combines systematic biopsy, the current primary diagnostic approach, with MRI-targeted biopsy, is poised to greatly improve prostate cancer diagnosis, thereby reducing the risk of both overtreatment and undertreatment of the disease. To see all open prostate cancer trials, click here. Read more...

FLC logo

Christian Hinrichs and Steve Rosenberg receive Federal Laboratory Consortium award

Mar 3, 2020

Christian Hinrichs, M.D., Investigator in the Experimental Transplantation and Immunotherapy Branch, and Steve Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, received an award from the Federal Laboratory Consortium for Technology Transfer (FLC) for their project, “New, First-in-class Immunotherapy for Treatment of Recurrent, Metastatic Cervical Cancer.” This award recognizes employees of FLC member laboratories and non-laboratory staff who have accomplished outstanding work in the process of transferring federally developed technology. Read more...

Metastatic melanoma cells

A new set of genes linked to metastasis in melanoma

Mar 3, 2020

CCR researchers have found that melanoma can reactivate gene expression patterns that are usually active in melanoblasts, facilitating their progression to metastatic behavior. These newly discovered melanoblast genes have the potential to provide a new source of pathways that could be tapped to develop new treatments for melanoma. Read more...

Pancreas anatomy

Clinical trial studies combination therapy for mesothelin-expressing solid tumors

Mar 3, 2020

A clinical trial at the NIH Clinical Center is evaluating a combination therapy for mesothelin-expressing solid tumors. Mesothelin is a protein found on the surface of certain types of normal cells and cancer cells. This trial is studying the effect of LMB-100, a man-made protein attracted to mesothelin, with a drug commonly used to treat certain types of arthritis and colitis. Read more...

breast cancer cell

Irinotecan shrinks DNA-repair-deficient breast cancers in patient-derived mouse models

Mar 2, 2020

Laboratory studies uncover genetic features that make some triple-negative breast cancers vulnerable to an overlooked treatment option. Read more...

Udo Rudloff

Udo Rudloff and team develop potential new type of immunotherapy

Mar 2, 2020

New research led by Udo Rudloff, M.D., Ph.D., Investigator in the Pediatric Oncology Branch, describes a potential new type of immunotherapy that applies across many types of cancer. The findings were reported in Science Translational Medicine and showed this approach has potential for treating other diseases as well. This work was featured in a recent press release from the National Center for Advancing Translational Sciences. Read more...

Infected cell nucleus

New study overturns conventional understanding of how HIV infection occurs

Feb 26, 2020

Researchers have succeeded in imaging where and when the protective coating that surrounds HIV is disassembled, a critical step in the viral replication process. Their observations show that the virus keeps its protective coating after entering the nucleus of a cell and then begins replicating, which is counter to what most scientists have thought for decades. Read more...

CAR T-cell therapy

Jennifer Brudno and James Kochenderfer discuss reduced side effects of remodeled CAR T-cell therapy

Feb 20, 2020

Jennifer Brudno, M.D., Assistant Research Physician, and James Kochenderfer, M.D., Investigator, both of the Surgery Branch, discussed their ongoing work to remodel CAR T cells to create a safer, more effective therapy in a recent Cancer Currents blog post. They share that since they tweaked the design of their original CAR T cells, the new therapy caused far fewer neurologic side effects than the original therapy did in an earlier trial but was equally effective.  Read more...

Cancer cells

Potent new LDHI inhibitor disrupts tumor growth in mice

Feb 13, 2020

Researchers have identified a potent LDH inhibitor, which can disrupt the energy production of tumors in mice. After exposure to the LDH inhibitor, the cancers cells began to rely on a different form of energy production, which could also be disrupted by using a second drug. Combining the two drugs had a potent anti-cancer effect. Read more...